Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment.

By Barry A. Borlaug, W. Paulus. European Heart Journal, 2011

1,077 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine, Radiology, Nuclear Medicine and Imaging

View Paper: https://www.semanticscholar.org/paper/11d01e25884a266c72ca8a5c9ab6a8c8e9166fe6

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cardiology and Cardiovascular Medicine

In Radiology, Nuclear Medicine and Imaging

Frank Flachskampf

Citations in the corpus

Clinical Recommendations for Cardiopulmonary Exercise Testing Data Assessment in Specific Patient Populations (2012, neutral): “Unique to CPX for this indication, a hypertensive response to exercise that coincides with exertional dyspnoea and exercise intolerance may be an early indicator of HF-PEF.”
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012 (2012, background): “Diabetes may be prevented by treatment with ARBs and possibly ACE inhibitors.197 Beta-blockers are not contraindicated in diabetes and are as effective in improving outcome in diabetic patients as in non-diabetic individuals, although different beta-blockers may have different effects on glycaemic i”
Pathological Ventricular Remodeling: Mechanisms: Part 1 of 2 (2013, background): “However, it is estimated that 50% of heart failure patients have a preserved LV ejection fraction, or HFpEF.6 Initial studies attributed HFpEF to dysfunction of the myocardium during the filling phase of the cardiac cycle; diastolic stiffness, prolonged isovolumic LV relaxation, and slow LV filling ”
2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the preventionof sudden cardiac death (2015, neutral): “In the past 10 years there has been increased awareness that many patients who have signs and symptoms of HF have a normal or preserved ejection fraction (HFpEF).(8,311) Many of the therapies that improve survival in HF with reduced ejection fraction (HFrEF) are less effective in HFpEF.”
Heart Failure With Preserved, Borderline, and Reduced Ejection Fraction: 5-Year Outcomes. (2017, background): “Comorbidities are frequently seen in HFpEF and likely contribute to the development of CV abnormalities and signs/symptoms of HFpEF (15).”
Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial. (2013, neutral): “Demographics Age, mean (SD), y 67 (8) 67 (8) 67 (8)”
Impaired Systolic Function by Strain Imaging in Heart Failure With Preserved Ejection Fraction (2013, background): “The underlying pathophysiology in patients with HFpEF has been commonly believed to involve impairment of diastolic function, with increased passive chamber stiffness (38,39).”
Cardiovascular disease in women (2010, neutral): “This syndrome was historically considered to be caused exclusively by left ventricular diastolic dysfunction, as demonstrated on echocardiography, but research has identified several other contributory factors, including limitations in left ventricular systolic reserve, systemic and pulmonary vascul”